Get started today

Medicinal Cannabis: A Budding Therapy for Dementia

Presented by Associate Professor Genevieve Steiner

About this module:

Alzheimer’s Disease is the second leading cause of death in Australians aged 65 years and over, and a leading cause of disability. It involves not only as cognitive decline and loss of memory but a range of neuropsychiatric symptoms. Scientific evidence indicates that the endocannabinoid system may be involved in the pathogenesis of Alzheimer’s Disease. Medicinal cannabis shows therapeutic potential to address the pathophysiology involved as well as many of the neuropsychiatric symptoms.

This module explores Alzheimer’s Disease, how the endocannabinoid system is involved and how cannabidiol and tetrahydrocannabinol may be able to address signs and symptoms associated with this disease.

This module is pitched at a level suitable for healthcare practitioners and those with a background in biomedical sciences. 

Associate Professor Genevieve Steiner

Associate Professor Genevieve Steiner is an NHMRC-ARC Dementia Research Development Fellow and Director of Research at the NICM Health Research Institute, Western Sydney University. Her cognitive neuroscience research spans the early detection, prevention, and treatment of cognitive decline in older people with the aim of reducing dementia risk and improving quality of life.
A/Prof Steiner’s current focus is on testing novel therapeutics that can provide early intervention for those at high risk of dementia, including a world-first medicinal cannabis trial for those with early-stage Alzheimer’s disease. A/Prof Steiner has attracted >$15M AUD in grant funding (>$6M as a CI), 19 awards and prizes, and has published >60 peer reviewed publications and presented at >40 international and national conferences.
Created with